MASS 908 Devices Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1555279 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY23.7%
TTM net income YoY-487.1%
TTM EPS YoY-384.6%
Revenue 3-yr CAGR11.5%
Net income 3-yr CAGR—
Margins
Gross margin52.3%
Operating margin-42.7%
Net margin-36.9%
FCF margin4.0%
EBITDA margin-34.9%
Returns
ROE-17.0%
ROA-12.4%
ROIC (approx.)-27.8%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets24.9%
Debt / equity0.00x
Current ratio5.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.12x
Accruals ratio-13.9%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $56.20M | $47.75M |
| Cost of revenue | $27.77M | $23.25M |
| Gross profit | $28.42M | $24.50M |
| R&D expense | $15.57M | $14.99M |
| SG&A expense | $38.53M | $39.46M |
| Operating income | -$39.42M | -$57.39M |
| Pretax income | -$33.34M | -$53.14M |
| Income tax | -$66,000 | -$282,000 |
| Net income | $19.49M | -$72.21M |
| EBITDA | -$34.96M | -$52.71M |
| EPS (basic) | 0.54 | -2.12 |
| EPS (diluted) | 0.54 | -2.12 |
| Weighted avg. shares (diluted) | 35.90M | 34.08M |
| Balance sheet | ||
| Cash & equivalents | $70.52M | $44.20M |
| Short-term investments | $42.45M | $25.57M |
| Receivables | $11.33M | $8.85M |
| Inventory | $12.99M | $10.89M |
| Current assets | $144.56M | $103.06M |
| PP&E, net | $4.23M | $1.59M |
| Goodwill | $0 | $0 |
| Intangibles | $36.41M | $38.68M |
| Total assets | $190.07M | $159.48M |
| Current liabilities | $34.06M | $25.15M |
| Total liabilities | $46.37M | $44.88M |
| Shareholders' equity | $143.70M | $114.59M |
| Shares outstanding | 36.32M | 35.10M |
| Cash flow statement | ||
| Operating cash flow | -$23.69M | -$30.25M |
| Capital expenditure | $955,000 | $602,000 |
| Free cash flow | -$24.64M | -$30.85M |
| Investing cash flow | $50.75M | -$46.32M |
| Financing cash flow | -$697,000 | -$376,000 |
| Depreciation & amortization | $4.46M | $4.68M |
| Stock-based compensation | $9.85M | $11.76M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.